Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells

Zhou Song1, Bo Wei1, Canrong Lu1

  • 1Department of General Surgery, General Hospital of Chinese PLA, Beijing 100853, P.R. China.

Insights

Metformin, an anti-diabetic drug, inhibits the Sonic hedgehog (Shh) signaling pathway in gastric cancer cells. This effect is dependent on AMP-activated protein kinase (AMPK), suggesting a potential therapeutic role for metformin in gastric cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Sonic hedgehog (Shh) signaling pathway is implicated in gastric cancer development.
  • Metformin, a common anti-diabetic medication, exhibits potential anticancer properties.

Purpose of the Study:

  • To investigate the effect of metformin on the Shh signaling pathway in human gastric cancer cells.
  • To determine the role of AMP-activated protein kinase (AMPK) in mediating metformin's effects on the Shh pathway.

Main Methods:

  • Human gastric cancer cell lines (HGC-27 and MKN-45) were treated with metformin.
  • mRNA and protein levels of Shh pathway components (Shh, SMO, Gli-1, Gli-2, Gli-3) were analyzed using Western blot and RT-qPCR.
  • RNA interference was employed to assess the involvement of AMPK.

Main Results:

  • Metformin significantly reduced Shh and Gli-1 mRNA and protein levels in a dose- and time-dependent manner.
  • Metformin also inhibited the expression of SMO, Gli-2, and Gli-3.
  • AMPK depletion reversed metformin's suppressive effect on Shh-induced Gli-1 expression.

Conclusions:

  • Metformin effectively inhibits the Shh signaling pathway in gastric cancer cell lines.
  • The inhibitory action of metformin on the Shh pathway is dependent on AMPK activation.